adamantane has been researched along with Autoimmune Diabetes in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chin, KL; Hawley, CM; Jun, M; Lo, C; Oshima, M; Toyama, T; Zoungas, S | 1 |
| Abdelaziz, RR; Abdelhamid, AM; Salem, HAA | 1 |
| Garg, SK; Giordano, D | 1 |
| Araújo, GR; Ávila, Dde L; Costa, DC; de Lima, WG; Diniz, MF; Miranda, PH; Pedrosa, ML; Silva, M; Silva, ME | 1 |
| Hirota, D; Kajitani, N; Kodera, R; Makino, H; Miyamoto, S; Oda, K; Ono, T; Shikata, K; Takatsuka, T; Usui, HK | 1 |
| Costa, DC; de Amorim Miranda, PH; de Lima, WG; Monteiro, OM; Rossoni, JV; Silva, ME | 1 |
| Gangadharan Komala, M; Gross, S; Panchapakesan, U; Pollock, C; Zaky, A | 1 |
| George, PS; McCrimmon, RJ | 1 |
| Deacon, CF; Dunning, BE; Foley, JE; He, YL; Holst, JJ; Kelley, DE; Leone-Jones, A; Ligueros-Saylan, M; Yu, T | 1 |
| Seissler, J | 1 |
| Ahrén, B; Farngren, J; Foley, JE; Persson, M; Schweizer, A | 1 |
3 review(s) available for adamantane and Autoimmune Diabetes
| Article | Year |
|---|---|
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Glycated Hemoglobin; Graft Survival; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Kidney Transplantation; Nitriles; Pioglitazone; Postoperative Complications; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Transplant Recipients; Vildagliptin | 2020 |
New Medications for the Treatment of Diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
[Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].
Topics: Adamantane; Contraindications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
3 trial(s) available for adamantane and Autoimmune Diabetes
| Article | Year |
|---|---|
Saxagliptin co-therapy in C-peptide negative Type 1 diabetes does not improve counter-regulatory responses to hypoglycaemia.
Topics: Adamantane; Adult; Blood Glucose Self-Monitoring; Cross-Over Studies; Diabetes Mellitus, Type 1; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Epinephrine; Female; Glucagon; Glucose Clamp Technique; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Monitoring, Ambulatory; Norepinephrine | 2016 |
Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 1; Feeding Behavior; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucagon-Secreting Cells; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Nitriles; Pyrrolidines; Vildagliptin; Young Adult | 2012 |
6 other study(ies) available for adamantane and Autoimmune Diabetes
| Article | Year |
|---|---|
Vildagliptin/pioglitazone combination improved the overall glycemic control in type I diabetic rats.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucagon; Glutathione; Glycated Hemoglobin; Insulin; Male; Malondialdehyde; Nitric Oxide; Nitriles; Pancreas; Pioglitazone; Pyrrolidines; Rats, Sprague-Dawley; Streptozocin; Superoxide Dismutase; Thiazolidinediones; Vildagliptin | 2018 |
Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
Topics: Adamantane; Animals; Antioxidants; Biomarkers; Blood Glucose; Body Weight; Catalase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Incretins; Insulin; Insulin-Secreting Cells; Nitriles; Oxidation-Reduction; Oxidative Stress; Pyrrolidines; Rats; Streptozocin; Superoxide Dismutase; Vildagliptin | 2013 |
Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glucagon-Like Peptide 1; Kidney Diseases; Kidney Glomerulus; Male; Nitriles; Protective Agents; Pyrrolidines; Rats; Rats, Sprague-Dawley | 2014 |
Vildagliptin induces β-cell neogenesis and improves the lipid profile in a later phase of type 1 diabetes.
Topics: Adamantane; Animals; Blood Glucose; Cell Proliferation; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipid Metabolism; Nitriles; Pyrrolidines; Rats, Inbred F344; Triglycerides; Vildagliptin | 2015 |
Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
Topics: Adamantane; Albuminuria; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Fibronectins; Fibrosis; Glomerulonephritis; Hypertrophy; Insulin; Kidney; Male; Mice, Knockout; Nephritis, Interstitial; Nitric Oxide Synthase Type III; Phosphorylation; Signal Transduction; Smad2 Protein; Smad3 Protein; Streptozocin; Transcription Factor RelA; Transforming Growth Factor beta | 2016 |
[Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 1; Exenatide; Humans; Insulin-Secreting Cells; Islets of Langerhans; Islets of Langerhans Transplantation; Mice; Nitriles; Peptides; Pyrazines; Pyrrolidines; Regeneration; Sitagliptin Phosphate; Stem Cell Transplantation; Transplantation, Heterologous; Triazoles; Venoms; Vildagliptin | 2008 |